Zibara Kazem, Zein Nabil El, Sabra Mirna, Hneino Mohammad, Harati Hayat, Mohamed Wael, Kobeissy Firas H, Kassem Nouhad
ER045, PRASE, Lebanese University, Beirut, Lebanon.
Faculty of Sciences, Biology Department, Lebanese University, Beirut, Lebanon.
Front Neurol. 2017 May 23;8:214. doi: 10.3389/fneur.2017.00214. eCollection 2017.
Thyroxine (T) enters the brain either directly across the blood-brain barrier (BBB) or indirectly the choroid plexus (CP), which forms the blood-cerebrospinal fluid barrier (B-CSF-B). In this study, using isolated perfused CP of the sheep by single-circulation paired tracer and steady-state techniques, T4 transport mechanisms from blood into lateral ventricle CP has been characterized as the first step in the transfer across the B-CSF-B. After removal of sheep brain, the CPs were perfused with I-T and C-mannitol. Unlabeled T was applied during single tracer technique to assess the mode of maximum uptake () and the net uptake () on the blood side of the CP. On the other hand, in order to characterize T protein transporters, steady-state extraction of I-T was measured in presence of different inhibitors such as probenecid, verapamil, BCH, or indomethacin. Increasing the concentration of unlabeled-T resulted in a significant reduction in %, which was reflected by a complete inhibition of T uptake into CP. In fact, the obtained % decreased as the concentration of unlabeled-T increased. The addition of probenecid caused a significant inhibition of T transport, in comparison to control, reflecting the presence of a carrier mediated process at the basolateral side of the CP and the involvement of multidrug resistance-associated proteins (MRPs: MRP1 and MRP4) and organic anion transporting polypeptides (Oatp1, Oatp2, and Oatp14). Moreover, verapamil, the P-glycoprotein (P-gp) substrate, resulted in ~34% decrease in the net extraction of T, indicating that MDR1 contributes to T entry into CSF. Finally, inhibition in the net extraction of T caused by BCH or indomethacin suggests, respectively, a role for amino acid "L" system and MRP1/Oatp1 in mediating T transfer. The presence of a carrier-mediated transport mechanism for cellular uptake on the basolateral membrane of the CP, mainly P-gp and Oatp2, would account for the efficient T transport from blood to CSF. The current study highlights a carrier-mediated transport mechanism for T4 movement from blood to brain at the basolateral side of B-CSF-B/CP, as an alternative route to BBB.
甲状腺素(T4)可直接穿过血脑屏障(BBB)进入大脑,也可间接通过形成血脑脊液屏障(B-CSF-B)的脉络丛(CP)进入大脑。在本研究中,采用单循环双示踪剂和稳态技术对绵羊的离体灌注脉络丛进行研究,T4从血液进入侧脑室脉络丛的转运机制已被确定为跨越B-CSF-B转运的第一步。去除绵羊大脑后,用125I-T4和14C-甘露醇灌注脉络丛。在单示踪技术过程中应用未标记的T4,以评估脉络丛血侧的最大摄取模式(Jmax)和净摄取量(Jnet)。另一方面,为了表征T4蛋白转运体,在存在不同抑制剂(如丙磺舒、维拉帕米、BCH或吲哚美辛)的情况下测量125I-T4的稳态摄取量。未标记T4浓度的增加导致Jmax显著降低,这表现为T4摄取进入脉络丛完全受到抑制。事实上,随着未标记T4浓度的增加,获得的Jmax降低。与对照组相比,添加丙磺舒导致T4转运受到显著抑制,这反映了脉络丛基底外侧存在载体介导的过程,以及多药耐药相关蛋白(MRPs:MRP1和MRP4)和有机阴离子转运多肽(Oatp1、Oatp2和Oatp14)的参与。此外,维拉帕米是P-糖蛋白(P-gp)的底物,导致T4的净摄取量降低约34%,表明MDR1有助于T4进入脑脊液。最后,BCH或吲哚美辛引起的T4净摄取量抑制分别表明氨基酸“L”系统和MRP1/Oatp1在介导T4转运中起作用。脉络丛基底外侧膜上存在细胞摄取的载体介导转运机制,主要是P-gp和Oatp2,这可以解释T4从血液到脑脊液的有效转运。当前研究突出了在B-CSF-B/脉络丛基底外侧存在T4从血液到大脑的载体介导转运机制,作为进入血脑屏障的另一条途径。